Golden opportunities for biotech bargain hunters  

Low stock market valuations make Nordic biotech companies attractive to potential investors
According to a report in today's Jyllands-Posten increasing numbers of stock quoted Nordic biotech companies are running low on operating cash. Jyllands-Posten refers to an analysis by Danske Securities which showed that over half of the companies surveyed have funds for at most another two years of operation. At the same time, several of these companies currently have very low stock market valuations, making it difficult for these companies to raise new capital themselves. For potential biotech investors however, they represent excellent opportunities to acquire patented technologies and products in development at bargain prices.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×